HN2012000576A - Formulaciones en comprimido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada - Google Patents

Formulaciones en comprimido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada

Info

Publication number
HN2012000576A
HN2012000576A HN2012000576A HN2012000576A HN2012000576A HN 2012000576 A HN2012000576 A HN 2012000576A HN 2012000576 A HN2012000576 A HN 2012000576A HN 2012000576 A HN2012000576 A HN 2012000576A HN 2012000576 A HN2012000576 A HN 2012000576A
Authority
HN
Honduras
Prior art keywords
trifluorometilfenil
hydroxibut
enoic
acid
ciano
Prior art date
Application number
HN2012000576A
Other languages
English (en)
Inventor
Gerrit Hauck
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2012000576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HN2012000576A publication Critical patent/HN2012000576A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS SOLIDAS QUE COMPRENDEN LA ( 4-TRIFLUOROMETILFENIL) AMIDA DEL ACIDO ( Z)-2- CIANO-3- HIDROXIBUT-2-ENOICO, ASI COMO PROCESOS PARA SU PREPARACION, A METODOS PARA UTILIZAR DICHAS COMPOSICIONES PARA TRATAR SUJETOS QUE PADECEN ENFERMEDADES AUTOINMUNOLOGICAS, EN PARTICULAR LUPUS ERITEMATOSO SISTEMICO O ENFERMEDAD DEL INJERTO FRENTE AL RECEPTOR CRONICA, ESCLEROSIS MULTIPLE O ARTRITIS REUMATOIDE.
HN2012000576A 2009-09-18 2012-03-16 Formulaciones en comprimido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada HN2012000576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290716 2009-09-18
US36338210P 2010-07-12 2010-07-12

Publications (1)

Publication Number Publication Date
HN2012000576A true HN2012000576A (es) 2015-01-26

Family

ID=41510564

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2012000576A HN2012000576A (es) 2009-09-18 2012-03-16 Formulaciones en comprimido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada

Country Status (40)

Country Link
US (5) US20120172427A1 (es)
EP (1) EP2477611B1 (es)
JP (1) JP2013505213A (es)
KR (1) KR101547880B1 (es)
CN (4) CN104666238B (es)
AR (1) AR078383A1 (es)
AU (2) AU2010297357B2 (es)
BR (1) BR112012006184B1 (es)
CA (1) CA2772275A1 (es)
CL (1) CL2015000047A1 (es)
CO (1) CO6511244A2 (es)
CR (2) CR20170078A (es)
CY (1) CY1119364T1 (es)
DK (1) DK2477611T3 (es)
DO (1) DOP2012000070A (es)
ES (1) ES2625731T3 (es)
GT (1) GT201200075A (es)
HK (2) HK1206245A1 (es)
HN (1) HN2012000576A (es)
HR (1) HRP20170904T1 (es)
HU (1) HUE032963T2 (es)
IL (3) IL218492A (es)
JO (1) JO3327B1 (es)
LT (1) LT2477611T (es)
MA (1) MA33585B1 (es)
ME (1) ME02765B (es)
MX (1) MX336663B (es)
MY (1) MY155613A (es)
NZ (2) NZ598744A (es)
PE (2) PE20121478A1 (es)
PL (1) PL2477611T3 (es)
PT (1) PT2477611T (es)
RS (1) RS56074B1 (es)
RU (2) RU2012115459A (es)
SI (1) SI2477611T1 (es)
TN (1) TN2012000061A1 (es)
TW (2) TWI522130B (es)
UA (2) UA115979C2 (es)
UY (1) UY32889A (es)
WO (1) WO2011032929A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121478A1 (es) * 2009-09-18 2012-11-12 Sanofi Sa Formulaciones en comprimido de teriflunomida: "(4'-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
AU2014352920A1 (en) * 2013-11-22 2016-06-23 Genzyme Corporation Novel methods for treating neurodegenerative diseases
CN103656657A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 特立氟胺药物组合物及制备方法
PL3122358T3 (pl) 2014-03-26 2021-06-14 Astex Therapeutics Ltd. Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US20180147148A1 (en) 2015-05-23 2018-05-31 Ftf Pharma Private Limited Pharmaceutical composition of teriflunomide
CA2996632C (en) 2015-09-01 2023-10-17 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers
WO2017037645A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical formulations of teriflunomide
WO2017056104A1 (en) * 2015-09-28 2017-04-06 Natco Pharma Limited Stable pharmaceutical compositions of teriflunomide
WO2017125841A1 (en) * 2016-01-20 2017-07-27 Emcure Pharmaceuticals Limited Pharmaceutical compositions of teriflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
SI3999038T1 (sl) * 2019-07-17 2024-05-31 Cytokinetics, Inc. Peroralne formulacije zaviralca srčne sarkomere
AU2021305052A1 (en) * 2020-07-07 2023-02-09 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
WO2022085015A1 (en) * 2020-10-24 2022-04-28 V-Ensure Pharma Technologies Private Limited A solid oral composition of teriflunomide
GR1010137B (el) 2020-12-15 2021-12-07 Φαρματεν Α.Β.Ε.Ε., Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης
TR202022336A2 (tr) * 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide
EP4382097A1 (en) 2022-11-25 2024-06-12 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising teriflunomide
WO2024112298A1 (en) * 2022-11-25 2024-05-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising teriflunomide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852294A (en) * 1968-08-27 1974-12-03 Merck Patent Gmbh Bis-quaternary pyridinium salts
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
CA2202904C (en) 1994-10-17 2006-12-19 Yukio Amano Pharmaceutical composition for prophylaxis and treatment of type i allergic diseases
ES2150808T3 (es) 1997-08-08 2000-12-01 Aventis Pharma Gmbh Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
HUP0301865A3 (en) 2000-02-15 2005-12-28 Teva Pharma A method for synthesizing leflunomide
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
CA2443285C (en) 2001-04-05 2007-08-21 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20050158371A1 (en) 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
GB2394660A (en) 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
JP2008517059A (ja) * 2004-10-19 2008-05-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド 炎症性腸疾患を治療するための(z)−2−シアノ−3−ヒドロキシ−ブタ−2−エン酸−(4’−トリフルオロメチルフェニル)−アミドの使用
TWI275029B (en) * 2005-11-18 2007-03-01 Hon Hai Prec Ind Co Ltd An embedded system and method for processing data thereof
JP2009524658A (ja) 2006-01-24 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド レベチラセタム製剤、及びそれらの製造方法
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
EP1990048A3 (en) 2007-05-08 2009-05-06 Ulrike Wiebelitz Therapy of benign prostatic hyperplasia (bph)
PE20121478A1 (es) * 2009-09-18 2012-11-12 Sanofi Sa Formulaciones en comprimido de teriflunomida: "(4'-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

Also Published As

Publication number Publication date
GT201200075A (es) 2014-05-14
CN104666238A (zh) 2015-06-03
CR20120116A (es) 2012-06-15
NZ617025A (en) 2014-03-28
MA33585B1 (fr) 2012-09-01
HUE032963T2 (en) 2017-11-28
LT2477611T (lt) 2017-06-26
WO2011032929A1 (en) 2011-03-24
TWI522130B (zh) 2016-02-21
UA107582C2 (uk) 2015-01-26
TW201117838A (en) 2011-06-01
IL244809B (en) 2019-03-31
US20170247319A1 (en) 2017-08-31
CN102596184A (zh) 2012-07-18
KR20120089461A (ko) 2012-08-10
US20120208880A1 (en) 2012-08-16
EP2477611B1 (en) 2017-04-05
UA115979C2 (uk) 2018-01-25
RU2681079C2 (ru) 2019-03-04
IL218492A (en) 2016-04-21
CO6511244A2 (es) 2012-08-31
IL264912B (en) 2019-11-28
MX336663B (es) 2016-01-27
RU2015151938A3 (es) 2019-01-15
PE20121478A1 (es) 2012-11-12
PE20152031A1 (es) 2016-01-14
CR20170078A (es) 2017-05-22
RU2015151938A (ru) 2019-01-15
HK1206244A1 (en) 2016-01-08
HRP20170904T1 (hr) 2017-09-08
IL244809A0 (en) 2016-04-21
AU2013257516B2 (en) 2015-09-17
AR078383A1 (es) 2011-11-02
KR101547880B1 (ko) 2015-08-27
AU2010297357B2 (en) 2013-11-07
CA2772275A1 (en) 2011-03-24
US8802735B2 (en) 2014-08-12
US20190241505A1 (en) 2019-08-08
DOP2012000070A (es) 2012-05-31
ME02765B (me) 2018-01-20
PL2477611T3 (pl) 2017-09-29
TN2012000061A1 (en) 2013-09-19
CL2015000047A1 (es) 2015-06-12
PT2477611T (pt) 2017-06-05
NZ598744A (en) 2013-11-29
CN104666238B (zh) 2018-04-06
CN104739821B (zh) 2018-04-06
MY155613A (en) 2015-11-13
TW201517935A (zh) 2015-05-16
SI2477611T1 (sl) 2017-07-31
UY32889A (es) 2011-04-29
US20140235888A1 (en) 2014-08-21
EP2477611A1 (en) 2012-07-25
RU2012115459A (ru) 2013-10-27
CN104666272A (zh) 2015-06-03
RS56074B1 (sr) 2017-10-31
CN102596184B (zh) 2015-03-11
ES2625731T3 (es) 2017-07-20
DK2477611T3 (en) 2017-07-10
TWI468190B (zh) 2015-01-11
MX2012003122A (es) 2012-04-10
BR112012006184B1 (pt) 2022-10-18
CY1119364T1 (el) 2018-02-14
HK1206245A1 (en) 2016-01-08
IL218492A0 (en) 2012-04-30
JO3327B1 (ar) 2019-03-13
AU2010297357A1 (en) 2012-04-05
BR112012006184A2 (pt) 2016-05-31
US20120172427A1 (en) 2012-07-05
JP2013505213A (ja) 2013-02-14
CN104739821A (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
HN2012000576A (es) Formulaciones en comprimido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
ECSP18048718A (es) Imidazolilimidazoles condensados como compuestos antivirales
UY33735A (es) Compuestos antivirales
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
DOP2014000244A (es) Compuestos novedosos
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
ECSP11010932A (es) Compuestos de azaindazol como antagonistas del receptor de ccr1
MY156702A (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
UY30917A1 (es) Moduladores 2-aminopiridina del receptor histamina h
DOP2011000402A (es) Composicion farmaceutica para la anticoncepcion de emergencia
BR112017022008A2 (pt) composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios
IN2012MN02923A (es)
NZ741724A (en) Renal cell populations and uses thereof
NZ712479A (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
CU24184B1 (es) Profármaco de adrenomedulina basado en polietilenglicol
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
MX2014005565A (es) Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos.
CL2016000677A1 (es) Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.
TN2015000135A1 (en) Modified release formulations for oprozomib
AR087168A1 (es) Compuesto derivado de pirimidina sulfonamida
NI201200041A (es) Formulaciones en comprimido de la (4' - trifluorometilfenil) amida del ácido (z) - 2 - ciano - 3 - hidroxibut - 2 - enoico con estabilidad mejorada
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.